Chronic Hepatitis News

VIENNA — In this exclusive video from the International Liver Congress 2019, Philippa Easterbrook, MD, senior scientist of the Global Hepatitis Program within the HIV Department at the WHO headquarters in Geneva, Switzerland, discusses the future of direct-acting antiviral access for children and adolescents with hepatitis C.

VIENNA — In this exclusive video from the International Liver Congress 2019, Olufunmilayo Lesi, FWACP, FMCP, from the University of Lagos in Nigeria, discusses the WHO’s goal for global elimination of viral hepatitis by the year 2030.

Arrowhead Pharmaceuticals began dosing in a new phase 1/2 study designed to evaluate a triple combination therapy that includes JNJ-3989 (formally ARO-HBV) and two undisclosed agents selected by Janssen Pharmaceuticals for the treatment of chronic hepatitis B, according to a press release.

In this exclusive video from the 2019 International Liver Congress, Anuj Gaggar, MD, PhD, vice president of clinical research in liver diseases at Gilead Sciences, highlights some of the company’s advances in hepatitis B.

The FDA approved revisions to the Viread product labeling to include safety and pregnancy-related outcome data from three published trials in pregnant women with chronic hepatitis B.

VIENNA — In this exclusive video from the International Liver Congress 2019, James Merson, PhD, global therapeutic area head for infectious diseases at Janssen, discusses the company’s pipeline for hepatitis B with a focus on improving functional cure rates.

VIENNA — In this exclusive video from the International Liver Congress 2019, Heather Valerio, from the Kirby Institute at the University of New South Wales in Australia, provides an overview of the Enhancing Treatment of Hepatitis C in Opioid Substitution Settings Engage study of hepatitis C outcomes among people who inject drugs.

VIENNA — In this exclusive video from the International Liver Congress 2019, Marc Bulterys, MD, PhD, team leader of the Global Hepatitis Program at the World Health Organization in Geneva, Switzerland, discusses the prevention, care and treatment of hepatitis B and hepatitis C among children and adolescents.

VIENNA — In the face of the remaining gaps in the hepatitis C care cascade, timely screening, monitoring and linkage to care by general practitioners coupled with early treatment by specialists could effectively reduce the hepatic and extrahepatic burden of the virus, according to a real-world analysis presented at the International Liver Congress 2019.

VIENNA — Patients with hepatitis C genotype 3 and compensated cirrhosis had higher rates of sustained virologic response after treatment with Epclusa and ribavirin than with Epclusa alone or combined Sovaldi and Daklinza with ribavirin.